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(C57BL/6 X DBA/2)Fl (B6D2F1) mice inoculated with 
parental DBA/2 (D2) splenocytes develop chronic 
stimulatory graft-versus-host reaction with many of 
the clinical manifestations of systemic lupus ery-
thematosus. This investigation tested the ability of 
8-methoxypsoralen (8-MOP) and ultraviolet A (UV A) 
light-treated D2 cells, primed to contain an ex-
panded population of T cells specific for B6D2F1 
major histocompatability complex antigens, to treat 
and/or prevent such systemic lupus erythematosus-
like disease. 8-MOPIUV A-treated cells from B6D2F1-
primed D2 donors were inoculated into B6D2F1 re-
cipients weekly six to ten times, either before or after 
initiating graft-versus-host disease with normal D2 
cells. A third group ofB6D2F1 recipients were vacci-
nated weekly six times before disease initiation using 
8-MOP/UV A-attenuated, B6D2F1-primed D2 cells 
that had been secondarily stimulated and expanded in 
vitro in the presence of irradiated B6D2F 1 targets and 
interleukin-2. Control B6D2F 1 m ice were vaccinated 
ost of the pharmacologic agents currently used 
in the treatment of various autoimmune disor-
ders n onspecific ally suppress immune function, 
and thus also hinder normal and desirable host 
responses. O ne of the major goals in the inves-
tigation of autoimmunity has been to identify methods which 
selectively suppress the immune response of only the self-reacting 
lymphocytes. Autoimmune states can be induced in animal models 
by inoculation with autoreactive T-cell lines or clones [1-3]. In 
addition, activated, sometimes oligo clonal, populations of T cells 
have been described in a variety of human autoimmune diseases 
[4-7]. The T-cell receptors (TCRs) of such oligo clonal autoreac-
tive T cells, in both animal models and human diseases of autoim-
munity, have been targets for specific (anti-idiotypic) immunother-
apy [8,9]. 
Extracorporeal photochemotherapy (ECPCT), also known as 
photopheresis, is a relatively new treatment for the leukemic form 
of the T -helper cell malignancy of cutaneous T -cell lymphoma 
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with 8-MOPIUV A-treated D2 cells stimulated in vitro 
and/or in vivo with (C3H1HeJ X DBA/2)Fl cells. Only 
mice vaccinated with 8-MOPIUV A-attenuated D2-
anti-B6D2F1 cells that were secondarily stimulated 
and expanded in vitro exhibited differences from con-
trols when measured by the clinical parameters of 
ascites formation, and mean survival (p < 0.025). 
These groups also differed significantly in mean an-
tinuclear antibody titer measured 14 weeks after 
disease initiation (p < 0.05). At 28 weeks, histologic 
evidence of systemic lupus erythematosus-like kid-
ney disease was found only in the control group. 
These results indicate that photochemically attenu-
ated D2-anti-B6D2F1 cells primed in vivo and sec-
ondarily stimulated and expanded in vitro are capa-
ble of vaccinating recipients against progression of 
graft-versus-host reaction-initiated systemic lupus 
erythematosus-like disease. Key words: graft-versus-host 
reactionlp hotopheresislsystemic lupus erythematosuslT-celi 
vaccination. J Invest D ermatol 104:177-182, 1995 
(CTCL) [10 - 12) . With each cycle of therapy, patients ingest the 
photoactivatable drug 8-methoxypsoralen (8-MOP) before their 
blood is removed, centrifuged to concentrate leukocytes, irradiated 
with ultraviolet A (UV A) light, and returned to the systemic 
circulation [9]. Although less than 10% of CTCL patients' periph-
eral blood lymphocytes (PBL) are exposed to UV A during each 
cycle of ECPCT, responding patients exhibit a disproportionately 
greater decrease in their estimated total body tumor burden of 
malignant cells, at the same time maintaining their normal T cell 
counts [10]. Such clinical responses are consistent with the hypoth-
esis that the photochemo-attenuated malignant T cells induce a 
host immune response directed against the entire malignant T -cell 
clone (i.e., treated and untreated cells). Because all of the malignant 
cells possess an identical T -cell receptor [13], it has been suggested 
that ECPCT operates through an anti-idiotypic T-cell vaccination 
mechanism [14]. 
The injection of parental (DBA/2; H_2d/d) lymphocytes into 
(CS7BL/6 X DBA/2)Fl [B6D2F1 ; H_2b/ d] mice produces a graft-
versus-host reaction (GVHR) of a chronic stimulatory type th at 
results in clinical and pathologic manifestations that resemble the 
human disorder systemic lupus erythematosus (SLE) [15]. Unlike 
some other murine models ofSLE [16-18] in which the pathogen-
esis is poorly understood, a clearly iden tifiable, host- antigen spe-
cific T -helper (T J cell population initiates the disease process in 
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the GVHR mice [19,20]. Tolerated graft (donor) T-helper cells 
with receptors specific for host allogeneic major histocompatibility 
complex class II (MHC-II) antigen I-A b apparently provide help for 
normally quiescent host (recipient) B cells, stimulating the produc-
tion of autoantibodies such as anti-double-stranded DNA (anti-
dsDNA) and antinuclear antibodies (ANA), ultimately resulting in 
lupus-like glomerulonephritis, ascites, and death [19]. Histologi-
cally, these mice display a diffuse proliferation of glomerular 
cellular elements that progresses to a hyalin-predominated glomer-
ular sclerosis [21]. 
The purpose of this investigation was to study the effects of 
repetitive inoculations ofB6D2F1 mice with extracorporeally pho-
tochemo-attenuated DBA/2 lymphocytes enriched for activated T h 
cells bearing TCRs specific for MHC-II(I-Ab ) antigens expressed in 
the B6D2F1 recipient (idiotype) on the prevention or treatment of 
the chronic SLE-like GVH disease induced in these Fl mice by 
injection of normal DBA/2 lymphocytes. It was hypothesized that 
photochemically treated I-A b -specific (idiotypic) T h cells might 
induce an anti-idiotypic host immune response against both the 
attenuated and the disease-mediating non-attenuated idiotypic 
cells, and result in decreased severity of SLE-like disease. 
MATERIALS AND METHODS 
Mice Female DBA/2 (D2, H_2 d / d ) mice were purchased from Harlan 
Sprague Dawley, Inc. (Indianapolis, IN). C57BL/6 (B6, H_2b/b), C3H/HeJ 
(C3H, H_2k/k), (C3H/HeJ X DBA/2)Fl (C3D2F1 , H_2k/d), and (C57BL/6 
X DBA/2)Fl (B6D2F1 , H_2b/d) mice were purchased from The Jackson 
Laboratories (Bar Harbor, ME). Mice were used at 6 to 8 weeks of age. 
Cells Donor mice were euthanized by methoxyflurane (Pitman-Moore, 
Inc., Mundelein, IL) overdose. Single-cell suspensions from pooled spleen 
and lymph nodes were prepared as described in [22]. Leukocyte viability 
was approximately 90% as determined by trypan blue exclusion. For 
IN VIVO PRIMING 
OF D2 MICE WITH 
Fl CELLS 
PROTOCOL I 
Group A Group B 
(Exp) (Control) 
B6D2Fl C3D2Fl 
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culture, cells were suspended either in supplemented RPMI 1640 (Gibco) 
containing 5% fetal bovine serum, 2 mM glutamine, 1 mM nonessential 
amino acids, 20 mM HEPES buffer, 100 U/ml penicillin/l00 ng/ml 
streptomycin, and 5 X 10 - 5 M 2-mercaptoethanol, or in phosphate-
buffered saline (PBS, Gibco) for treatment with 8-MOP/UVA. 
Photochemical Attenuation Spleen and lymph node (LN) cells were 
obtained from D2 donors primed 6 d earlier by the intravenous injection of 
50 X 106 semiallogeneic B6D2F1 spleen and LN cells. Cells were incubated 
in various concentrations (0-200 ng/ml) of 8-MOP (Sigma Chemical, St. 
Louis, MO) for 20 min at room temperature and then exposed to 1 J/cm2 
UVA (see below). After washing, 105 cells were plated in triplicate wells of 
a round bottom micro-titer plate (Becton-Dickinson, Lincoln Park, NJ) in 
a final volume of 200 J.LI of supplemented RPMI 1640 containing either 5 
U/ml recombinant human interleukin 2 (rIL-2; Amgen Biologicals, Thou-
sand Oaks, CA) or 105 x-irradiated (2000 rads) semiallogeneic B6D2F1 
spleen and LN cells [one-way mixed lymphocyte reaction (MLR)]. Cells 
were assayed for proliferation 48, 72, and 96 h after a 24-h pulse with 1 J.LCi 
of 3H-thymidine (Amersham, Arlington Heights, IL), using a PHD Cell 
Harvester (Cambridge Technology, Inc., Cambridge, MA) and a 1214 
Rackbeta liquid scintillation counter (Pharmacia LKB Nuclear, Inc., Gaith-
ersberg, MD) . 
UV A Irradiation Aseptically isolated mixed spleen and LN cells were 
isolated from DBA/2 mice 6 d after priming with 50 X 106 semi-allogeneic 
B6D2F1 cells, and treated with 8-MOP and UVA. The irradiation unit 
consisted of six UV A fluorescent tubes (FS40 Sylvania) emitting broad-band 
UV A energy in the wavelength of 320 to 400 nm. Emission in the UVA 
range was filtered out by a one quarter-inch thick sheet of plate glass. The 
UV A dose was monitored by a photometer (International Light, IL 700A) 
equipped with a UV A probe. Cells were recovered with the aid of a cell 
scraper (Falcon, Becton Dickinson & Co., Oxnard, CA), and washed with 
HESS before inoculation into Fl recipients . 
Vaccination and Challenge Protocols The three protocols employed 
in this study are depicted in Fig 1. 
PROTOCOL II PROTOCOL III 
Group C Group D Group E Group F 
(Exp) (Control) (Exp) (Control) 
B6D2Fl C3D2Fl B6D2Fl C3D2F1 
In Vitro Restimulation 
and Expansion 
PHOTOCHEMO-
ATIENUATION 8-MOP/UV A TREATMENT OF D2 CELLS 
VACCINATION 
& CHALLENGE 
SCHEDULES 
6 Weekly Innoculations of Attenuated Cells 
Into B6D2Fl Mice One Week PRIOR to 
G VHR Initiation With Normal 
Unmodified D2 Cells 
10 Weekly Innoculations 
One Week AFTER GVHR 
Initiation With Normal 
Unmodified D2 Cells 
Figure 1. Experimental design. Three related, but distinct, protocols were used to test the capacities of 8-MOP IUV A-attenuated D2 (I_Ad) lymphocytes 
to prevent (protocols I and II) or treat (protocol III) SLE-like GVH disease induced in B6D2F1 (I-A b i d) mice by injection of normal unmodified D2 (I_Ad) 
lymphocytes. Each protocol included an experimental and a control group: in experimental groups A, C, and E, the alloantigen-primed cells were obtained 
from D2 (I_Ad) donors immunized against the relevant B6 (I_Ab) MHC-II alloantigens (d anti-b); in control groups B, D, and F the D2 donors were 
immunized against the irrelevant C3H (I_Ak) MHC-II alloantigens (d anti-k). Protocol I and II B6D2Fl recipients received six weekly intravenous injections 
of 8-MOP/UV A inactivated alloantigen-activated D2 cells prior to initiation of the GVHR. In protocol III the Fl recipients received 10 weekly injections 
of 8-MOP IUV A-treated alloantigen-primed D2 cells beginning 1 week after initiation of the GVHR. The only differences between protocol I and protocol 
II were in the preparation of the alloantigen-primed D2 cells and the numbers of such cells used for the weekly vaccinations. In protocol I the D2 cells were 
primed in vivo and each recipient was injected with 50 X 106 such cells; in protocol II the D2 cells were primed in vivo and then secondarily restimulated 
and expanded in vitro before injection of 30 X 106 cells/recipient. 
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To obtain populations of in vivo alloantigen-primed lymphocytes, D2 
mice were primed with an intravenous inoculation of 50 X 106 spleen and 
LN cells from normal B6D2F1 or C3D2F1 donors. Six days later, the D2 
recipients were euthanized and spleen and LN cell suspensions prepared. 
Approximately one-half of these in vivo primed cells were then treated with 
8-MOP/UV A, and subsequently inoculated (50 X 106 cells/recipient) into 
panels of 5-6 B6D2F1 mice of protocol I or protocol III. The remaining 
primed DBA/2 cells were placed in culture (see immediately below) for 
secondary stimulation/expansion of the anti-allogeneic cell population 
before photochemo-attenuation and inoculation (30 X 106 cells/recipient) 
into panels of 5-6 B6D2F1 mice of protocol II. 
The cells were secondarily exposed to antigen il1 vitro co-culture in 
supplemented RPMI with x-irradiated (2000 rads) F] cells (either B6D2F or 
C3D2Fl) for 3 d at a 1: 1 ratio, and then further expanded in supplemented 
RPMI containing 5 U/ml of recombinant interleukin-2 (rIL-2; Amgen 
Biologicals, Thousand Oaks, CA) for four more d . Cells were then washed 
and resuspended in PBS for photochemo-attenuation and vaccination of Fl 
recipients in groups C and D (protocol II). 
One week after receiving the last of six vaccinations for protocol I and II , 
and one week prior to the administration of 1 0 vaccinations for protocol III, 
the B6D2F1 mice were challenged intravenously with 100 X 106 freshly 
isolated, individual D2 spleen and LN cells to initiate a parent ~ Fl GVHR; 
this challenge dose was twice that found previously to reliably initiate 
SLE-like disease [23]. The number of weekly repetitive vaccinations utilized 
in the different protocols in this study (from 6 to 10) was arbitrarily chosen 
to be in the same general range of vaccination frequencies utilized in 
previously published mouse models [17,22]; no studies to date (including 
this one) have systematically evaluated the effects of variations in vaccina-
tion frequency. 
Detection of Anti-Nuclear Antibodies Methoxyflurane-anesthetized 
mice were bled (300 jLl) with a Pasteur pipette via the retro-orbital plexus 
2,4,8, and 14 weeks after initiation of the GVHR. Serum was isolated from 
the centrifuged clotted samples and stored at - 20DC until testing. 
Anti-nuclear antibodies (ANA) were detected using an IFA kit of fixed 
human epithelial cell :; (Hep-2) (Quidel Corporation, San Diego, CA), 
testing serial dilutions of serum beginning at 1 :40. Tests were scored by a 
blinded observer as (-) or (+), using as a negative control pooled nonnal 
C5 7BL/ 6 and C3H/HeJ sera, and as a positive control a 1 :40 dilution of 
pooled sera from six-month- old autoimmune MLR/lpr mice (courtesy of 
Dr. Nicholas Crispe, Yale University, New Haven, CT) . 
Clinical Criteria Mice were examined for ascites at weekly intervals; 
animals displaying apparent abdominal distention on inspection were further 
examined by palpating their distended abdomens for detection of fluid. 
Those animals satisfYing the two criteria of inspection and palpation were 
considered positive for ascites. Survival was r~corded at weekly intervals. 
Kidney Histology Twenty-eight weeks after the initiation of the 
GVHR, two randomly chosen mice from protocol II, group C and the one 
mouse still alive from protocol II, group D were euthanized, and their left 
kidneys removed, fixed in formalin, embedded in paraffin, sectioned (5 jLm 
thickness), and stained with hematoxylin and eosin. Specimens were 
photographed at 100 X magnification. 
Statistical Analysis Differences between means were analyzed using the 
paired Student t test. A p value less than or equal to 0.05 was considered 
statistically significant. Proliferation assay data points (i.e., mean cpm) were 
displayed with bars that reflect ± 1 SEM of triplicate samples. 
RESULTS 
Determination of Minimum Effective Attenuation Dose of 
8-MOP/UVA The B6D2Fl-primed D2 spleen and LN cells 
pretreated with either no 8-MOP or 50 ng/ml 8-MOP and 1 ]/cm2 
UVA and then cultured in media containing 5 U/ml rIL-2 demon-
strated increasing proliferation between 48 and 96 h of culture (Fig 
2A). In contrast, cells treated with 100 ng/ml or more of 8-MOP 
and then 1 ]/cm2 UVA showed only background proliferative 
responses. Similarly, as shown in Fig 2B, when cultured with 
irradiated B6D2F 1 stimulator cells, only the B6D2Fl-primed D2 
cells treated with 8-MOP doses of 0 ng/ml and 50 ng/ml showed 
proliferative responses above background levels. Thus, the mini-
mum concentration of8-MOP used in conjunction with 1 ]/cm2 of 
UV A for in vivo primed cells to completely attenuate their prolif-
erative response to either IL-2 or to irradiated semi-allogeneic 
stimulator cells was approximately 100 ng/ml. This dose was 
subsequently utilized to photochemically attenuate the in vivv-
50000 
40000 
::E 
Q. 30000 0 
t: 
as 
CD 20000 
::E 
10000 
0 
50000 
40000 
::E 
Q. 30000 0 
t: 
as 
CD 20000 ::E 
10000 
o 
PHOTOPHORESIS IN A GHUR MODEL OF SLE 179 
a 
0 
b 
o 
50 
Dose 
50 
Dose 
• Pulsed at 24hr 
• Pulsed at 48hr 
.. Pulsed at 72hr 
100 150 200 
8-MOP (ng/ml) 
• Pulsed at 24hr 
• Pulsed at 48hr II Pulsed at 72hr 
100 150 200 
8-MOP (ng/ml) 
250 
250 
Figure 2. Minimum effective dose of 8-MOPIUV A to inhibit T-cell 
proliferation is 100 ng/ml of 8-MOP and 1 J/cm2 UVA. B6D2F1 -
primed D2 spleen and LN cells were treated with 0, 50, 100, 150, 200, or 
250 ng/ml 8-MOP and 1 Jlcm 2 UV A. Samples of105 cells were cultured in 
the presence of (a) 5 U/ml rIL-2 alone or (b) 105 irradiated target B6D2F1 
celis, and then assayed for their proliferative responses as measured by 
3H-thyrnidine incorporation (pulsed 24 h before harvesting at 48 , 72, and 
96 h). Each bar represents the mean cpm ± SEM of triplicate wells. The 
lowest effective dose of 8-MOP in conjunction with 1 J / cm2 UV A was 
determined to be 100 ng/ml in both instances. 
primed and in vitrv- boosted alloreactive D2 cells pnor to their 
inoculation into B6D2F1 recipients. 
Survival Twenty-eight weeks after the initiation of GVHR, four 
of the five group C mice were still alive and appeared clinically 
healthy; in contrast, only one of the 5- 6 mice in each of the other 
groups remained alive and all of these appeared chronically ill 
(ruffled fur, wasting). At this point the study was terminated by 
sacrificing the remaining mice. Survival times for all mice is shown 
in Table I; all mice sacrificed at the termination of the study were 
assigned a survival time of 28 weeks irrespective of their clinical 
appearance. The only significant difference in survival was between 
group C (mean survival 27.6 ± 0.4 weeks) and group D (mean 
survival 17.0 ± 2.4 weeks; p < 0.05). 
Examination for Serum ANA Because of the clear evidence 
for a difference in SLE-like disease progression only between 
groups C and D of protocol II (see above), only sera from these 
mice were analyzed for the presence of autoantibodies character-
istic of SLE-like disease. As shown in Fig 3 , comparison of mean 
ANA titers 2-14 weeks after GVHR initiation [calculated as 10g2 
(mean titer/40) + 1] showed a significant difference at week 14 
(2.60 ± 0.39 for group C versus 5.33 ± 1.67 for group D; p < 
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Table I. Survival Dataa 
Survival (weeks) of Individual Mice Mean Survival 
(weeks :!:: 
N Exper.rrnentalGroup 1 2 
6 Group A 12 14 
5 Group B 12 14 
5 Group C 28 26 
6 Group D 16 18 
5 Group E 18 16 
5 Group F 26 14 
3 4 
14 16 
14 14 
28 28 
14 28b 
28b 18 
14 28b 
5 
18 
28b 
28 
12 
16 
14 
6 
14 
SEM) 
17.0:!::2.4 
16.4 :!:: 2.9 
27.6 :!:: 0.4< 
17.0 :!:: 2.4< 
19.2:!::2.1 
19.2 :!:: 2.9 
a The survival of individual mice from each of six experimental groups (see Fig 1 for details) is reported. The experiment was terminated at week 28 after the initiation ofGVHR. 
Only groups C and D (protocol II) displayed a significant difference in mean survival (p < 0.05) . 
b Mouse clinically ill at time of sacrifice. 
c p < 0.05. 
0.05). (In comparison to these titers, pooled sera from 6-month-
old autoimmune MLRllpr mice gave a titer of 8.0.) Analysis of the 
same sera for the presence of antibodies to double-stranded DNA 
(indirect immunofluorescence using Crithidia lucilae as the substrate) 
revealed no significant differences between group C and group D in 
prevalence (approximately 60%) or titers (>1:10, <1:100) of such 
autoantibodies; pooled normal C57BL/6 sera was negative in the 
same assay, whereas the pooled autoimmune MRL/lpr sera give a 
titer of >1:100, <1:1000 (data not shown). 
Ascites Formation Protocol II experimental group C was the 
only group in which no mice (none of five) ever exhibited 
detectable ascites. In contrast, four of six mice in control group D 
of protocol II developed detectable ascites, beginning as early as 4 
weeks after the initiation of GVHR (p < 0.001). All of the four 
group D mice with detectable ascites died within 16 weeks of the 
initiation of their GVHR. Of the two group D mice in which ascites 
was never detected, one survived until week 18, and the other was 
sacrificed at week 28. 
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Figure 3. Experimental mice (group C) have lower mean ANA 
titers than control mice (group D) 14 weeks after induction of 
GVHR. ANA titers were represented in the form given by the equation 
[log2 (titer/40) + 1] such that a titer of 1:40 corresponded to a value of 1, 
1:80 to 2, 1:160 to 3, and so on. Means are plotted with bars indicative of 
:!:: SEM. ANA titers were determined for protocol II group C (solid squares) 
and protocol II group D (open circles) at 2, 4, 8, and 14 weeks after the 
initiation of GVHR. A statistically significant difference in mean ANA titer 
between the two groups was observed at week 14 (p < 0.05; n = 5 for 
group C and 3 for group D). 
Examination of Kidney Histopathology To look for his-
topathologic evidence of glomerulonephritis described both in 
GVHR SLE-like disease in mice [21] as well as in idiopathic SLE in 
humans [24], the kidneys from two mice (numbers 3 and 4) chosen 
at random and sacrificed at week 28 from group C and the one 
mouse (number 4) still surviving at that time in group D were 
processed for routine histopathologic evaluation. Although the 
sections were initially read blindly by a board-certified pathologist 
(P.H.), the differences between the groups were obvious even to 
less experienced observers. Kidney sections from a normal unin-
jected mouse (not shown) and from the group C mice (Fig 4A) 
displayed no evidence of either SLE-like glomerular disease (i.e., 
either early mesangial proliferation or late glomerular sclerosis), or 
renal tubule disease. In contrast kidney sections from the group D 
mouse (Fig 4B) demonstrated glomeruli showing striking hyalin-
ization consistent with a global glomerular sclerosis classically seen 
in late SLE [21,24], and the renal tubules appeared dilated and filled 
with proteinacious material. 
DISCUSSION 
The injection of more than 50 X 106 unmodified, naive D2 cells 
into B6D2F 1 mice induces the manifestations of chronic GVHR 
SLE-like disease [23]. It is the small percentage of donor D2-
anti-B6 [more specifically, D2-anti-MHC-II(I-Ab)] Th cells that 
proliferate in response to recipient semi-allogeneic B6D2F 1 cells 
after inoculation, and mediate the stimulatory GVHR [19]. We 
were concerned that too Iowa dose of8-MOP/UVA would result 
in incomplete attenuation of in vitro and/or in vivo B6-primed D2 
cells , and that inoculation of such cells could have initiated disease 
instead of preventing it. Therefore, it was necessary to first 
determine the minimum concentration of 8-MOP (at a constant 
UV A dose of 1 J / cm 2) that would completely attenuate D2 cells 
cultured either with IL-2 alone or with x-irradiated B6D2F1 
stimulator cells. For both conditions, this concentration was found 
to be 100 ng/ml, an amount similar to that previously found [25] to 
attenuate mitogen activated human T cells. Because that same study 
had demonstrated that, in the absence of 8-MOP, even doses of 
UV A up to 5 J / cm 2 were unable to completely attenuate lympho-
cyte proliferation, no attempts were made to incorporate into the 
experimental design of the present study groups of mice vaccinated 
with alloreactive lymphocytes pretreated with UV A alone. 
Repetitive vaccination with inactivated 8-MOP/UV A-treated 
cells from D2 donors primed in vivo with B6D2F 1 cells was found 
to be unable to prevent (protocol I) or treat (protocol III) progres-
sive SLE-like disease induceG in Fl recipient mice challenged with 
unmodified D2 cells. Strikingly different results were observed 
when mice were pretreated with cells from B6D2Fc primed D2 
donors that were secondarily stimulated in vitro with irradiated 
B6D2F1 cells prior to their photochemo-attenuation and inocula-
tion (protocol II); the mean survival of experimental mice (group 
C, treated with D2-anti-B6D2F1 cells) was over 27 weeks, com-
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Figure 4. SLE-like nephritic changes in kidneys of control mice (group D) versus normal renal histology in experimental mice (group C). 
Mice were sacrificed from group C (numbers 3 and 4) and group D (number 4) 28 weeks after the initiation ofGVHR. The left kidneys were fixed, sectioned 
at 5 J.Lm thickness, and stained with hematoxylin and eosin. A representative section from group C mouse 3 (Fig 4A) shows normal glomeruli (arrows) and 
normal renal tubules (asterisk). In contrast, the glomeruli from group D mouse 4 (Fig 4B) show frank glomerular sclerosis (arrows) and dilated renal tubules 
filled with proteinacious material (asterisk), consistent with changes secondary to severe GVHR SLE-like nephritis. Bar, 100 J.Lm. 
pared with a mean survival of just 17 weeks in control mice (group 
D, treated with D2-anti-C3D2F1 cells). 
These two groups also differed significantly in their serum ANA 
titers 14 weeks after disease initiation and in their incidence of 
developing detectable ascites. In the GVHR model of SLE-like 
disease, ascites is known to result from the hyperalbuminuria 
secondary to immune complex glomerulonephritis-induced renal 
failure, probably the principal cause of death in chronic GVHR in 
mice [21] and a substantial cause of death in human lupus [24]. At 
28 weeks after the initiation of GVHR, kidney disease in the 
longest surviving control mouse was confirmed by histologic 
examination, which showed marked glomerular sclerosis consistent 
with the late changes of immune complex-mediated glomerulone-
phritis described in SLE. In contrast, the kidneys from the experi-
mental (group C) mice could not be distinguished from those of 
normal mice. 
The secondary in vitro restimulation ofB6D2Fc primed D2 cells 
with irradiated B6D2F 1 cells followed by rIL-2- driven expansion 
of the activated cells was the apparent difference in the successful 
vaccination of protocol II group C mice compared with the 
protocol I group A mice. This finding is consistent with previous 
reports of the requirement for successful T-cell vaccination in a rat 
model of experimental allergic encephalomyelitis that T cells be 
activated in vitro by antigen-pulsed antigen-presenting cells [26] or 
with the mitogen concanavalin A [27] prior to attenuation. 
The present study did not reveal any obvious differences in 
SLE-like disease progression between the experimental and control 
groups of mice in protocol III, in which the repetitive vaccinations 
with in vivo primed D2-anti-B6 (or D2-anti-C3) cells were begun 
only after the inoculation with disease-initiating D2 cells. Given the 
obvious differences in disease progression noted immediately above 
between the experimental groups in protocols I and II (vaccinations 
completed bifore disease initiation), it is certainly possible that in vivo 
primed D2-anti-B6 cells secondarily activated and expanded in vitro 
would also have the capacity to ameliorate disease initiated prior to 
repetItIve vaccination with photochemo-attenuated cells. On the 
other hand, in other animal models of T-cell vaccination, it has 
repeatedly been shown to be more difficult to ameliorate pre-
existing disease than to ameliorate disease by vaccination prior to 
disease initiation [2]. 
Theoretically, recent in vitro T-cell activation might induce cell 
changes that enhance the presentation of TCR idiotype for recog-
nition by putative down-regulatory (suppressor and/or cytotoxic) 
T cells . T cells have been shown to recycle their MHC-I molecules 
via the endocytic pathway [28]. Perhaps recently activated T h cells 
more efficiently internalize their cell surface MHC-I molecules and 
their TCRs, enabling them to more effectively present TCR-
derived peptides in the context of MHC-I [29]. It is also possible 
that such activation facilitates the processing of newly synthesized 
TCR proteins for presentation in association with newly synthe-
sized MH C-1. 
Alternatively, the relative success of in vitro stimulated and 
expanded T cells to vaccinate may be based solely on the number of 
relevant (idiotype-bearing) T cells used for vaccination. Thus, even 
though fewer total cells were used in the weekly inoculations of 
protocol II mice (30 X 106 ) than in inoculations of protocol I and 
III mice (50 X 106 ), it is likely that a substantially higher proportion 
of the in vitro antigen-restimulated and rIL-2 expanded cells used to 
inoculate protocol II group C mice expressed the appropriate 
idiotype, i.e., D2-anti-B6 [MHC-II-(I-Ab)]. If successful ECPCT 
of CTCL acts via aT-cell vaccination mechanism, it is conceivable 
that the apparently greater clinical efficacy of this modality in 
leukemic, erythrodermic CTCL patients than in those with plaque-
stage disease who had less obvious peripheral blood involvement 
[14] also reflects differences in the numbers of circulating clonal 
(idiotypic) T cells available as potential immunogens. 
This investigation has clearly demonstrated that the SLE-like 
disease in B6D2F1 mice that follows the initiation of a chronic 
stimulatory GVHR by inoculation with D2 cells can be substan-
tially diminished by the prior vaccination of recipient B6D2F1 mice 
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with 8-MOP IUV A-attenuated D2-anti-MHC-II(I-A b) (idiotype) 
T cells primed in vivo and secondarily activated and expanded in 
vitro. This chronic GVHR model of SLE has the advantage over 
spontaneous models of SLE (MLRllpr and NZB/NZW mice) of 
having a clearly identified population of pathologic T h cells with a 
known idiotype [D2-anti-MHC-II-(I-A b)]. Thus it may be a useful 
model for elucidating whether successful photopheresis is in fact 
mediated by an anti-idiotypic immune response. 
The present studies have laid the groundwork for a number of 
future experiments that not only might provide more definitive 
evidence that ECPCT can act via an anti-idiotypic vaccination, but 
also might elucidate more of the details of such a mechanism. The 
experimental conditions for detecting anti-idiotypic cells in vacci-
nated mice need to be evaluated. Spleen and LN cells from 
vaccinated mice obtained shortly after the last vaccination (prior to 
disease initiation) could be assayed in vitro for alloantigen-specific 
suppressor effects, e.g., the capacity of cells from B6D2F1 cells to 
spec~cally suppress the capacity ofD2 cells to respond to irradiated 
B6D2F1 stimulator cells. Additional informative studies could 
include determining the phenotype(s) of such down-regulating 
cells by fractionating the putative anti-idiotypic T cells into purified 
CD4 + and CD8+ cells, prior to testing for their effects when 
cultured with appropriate idiotype-positive responder cells and 
alloantigenic stimulator cells. Additional in vivo experiments could 
be conducted to test the relative capacities of purified CD4 + and/or 
CD8+ anti-idiotypic T cells to adoptively transfer resistance to 
SLE-like GVH disease. 
In summary, this investigation has provided data consistent with 
the possibility that vaccination with photochemo-attenuated cells 
(such as in ECPCT) may eventually prove to be useful for the 
treatment of autoimmune disorders mediated by clones of autore-
active T cells of known (or, for that matter, unknown) specificity. 
It has reinforced previous findings that if autoreactive T cells are 
further activated and expanded in vitro before photochemo-atten-
uation, they are more effective in preventing disease. It has 
demonstrated the utility of the murine GVHR model of SLE-like 
disease to further study anti-idiotypic T cell vaccination using 
photochemo-attenuated cells. This model may also be useful for 
determining whether alternate methods of lymphocyte attenuation 
(e. g. , x-irradiation) used in T-cell vaccination protocols can be as 
effective as 8-MOP/UV A treatment. 
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